Belumosudil Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 200 mg

Reference Brands: Rezurock (USA)

Category: Immune Disorder

Product Description:

Belumosudil, marketed under the brand name Rezurock, is an oral targeted therapy used for the treatment of chronic graft-versus-host disease (cGVHD), a serious immune-mediated complication that can occur following allogeneic stem cell transplantation. It belongs to the class of serine/threonine kinase inhibitors and is specifically designed to inhibit Rho-associated coiled-coil kinase 2 (ROCK2).

ROCK2 plays a central role in regulating immune cell signaling pathways involved in inflammation and fibrosis. By selectively inhibiting ROCK2, belumosudil helps rebalance pro- and anti-inflammatory immune responses, thereby reducing chronic immune activation and tissue damage associated with cGVHD. This targeted mechanism allows for immune modulation without broad immunosuppression.

Preclinical and cellular studies have shown that belumosudil also influences several key biological pathways, including oxidative phosphorylation, WNT signaling, angiogenesis, and KRAS signaling. These additional effects may contribute to its therapeutic benefits in controlling immune dysregulation and fibrotic processes.

Administered orally, Rezurock provides a convenient treatment option for patients with limited alternatives after failure of prior systemic therapies. Its targeted approach represents an important advancement in the management of chronic graft-versus-host disease, offering improved disease control and quality of life for affected patients.